JABSOM’s IBR develops new technique to produce transgenic mice

By Kathleen Kihmm Connolly, PhD

Since Dr. Ryuzo Yanagimachi (Perry, et al., 1999) created the first transgenic mouse via intracytoplasmic sperm injection (famous fluorescent mice), the John A. Burns School of Medicine (JABSOM) has been a leader in gene technology. Professor Stefan Mosiyadi, of the Institute for Biogensis Research (IBR) founded by Dr. Yanagimachi, has developed a new mouse transgensis technique called transposase-enhanced pronuclear microinjection (te-PNI). This method is significant since it yields a greater successful transgenic mouse percentage than current methods used today.

This new technique may have a direct impact on the health and quality of life for people suffering from diseases such as cancer, diabetes, asthma and mental illness. In addition, the use of animal models can also provide insight to therapies for those carrying the genetic potential, but who have not yet manifested disease. There is no doubt that disease may be caused by several factors and gene interactions, however, the use of transgenic animal models in disease research is a significant component in understanding the factors, causes and potential therapies to treat many diseases.

To read more, click onto our new TECH TALK JABSOM website. Each month, Kathleen Kihmm Connolly, PhD will feature new, in-depth stories about research at the University of Hawai`i’s medical school.

Our featured photograph shows Dr. Mosiyadi outside the IBR at UH-Mānoa.